FDA places clinical hold on RGX-121 after spine MRI findings

Regulatory authorities placed a clinical hold on RGX-121 for Hunter Syndrome as asymptomatic spine nodules were discovered; the company anticipates limited near-term shareholder value impact due to focus on near-term catalysts in other programs.